MS-275 |
MS-27-275 |
ENTINOSTAT |
MS-275-27 |
SNDX-275 |
BAY 86-5274 |
MS 27-275 |
N-[[4-[(2-AMINOANILINO)-OXOMETHYL]PHENYL]METHYL]CARBAMIC ACID 3-PYRIDINYLMETHYL ESTER |
SNDX 275 |
BAY86-5274 |
MS 275 |
N-(2-AMINOPHENYL)-4-(N-(PYRIDIN-3-YLMETHOXYCARBONYL)AMINOMETHYL)BENZAMIDE |
chemidplus:209783-80-2 |
chembl:CHEMBL27759 |
pubchem.compound:4261 |
drugbank:11841 |
FDA Approval | not approved |
Drug Class | Small molecule |
Drug Indications | antineoplastic agent |
inhibitor (inhibitory) |
Novel drug target | Established target |
Trial Name | entinostat, SNDX-275, MS-275 |
Notes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Histone deacetylase inhibitor |
Trial Name | entinostat, SNDX-275, MS-275 |
inhibitor (inhibitory) |
Mechanism of Interaction | Histone deacetylase inhibitor |
Direct Interaction | yes |
Notes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Histone deacetylase inhibitor |
inhibitor (inhibitory) |
Mechanism of Interaction | Histone deacetylase inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Histone deacetylase inhibitor |
inhibitor (inhibitory) |
Mechanism of Interaction | Histone deacetylase inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Histone deacetylase inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Histone deacetylase inhibitor |
n/a |
combination therapy | Entinostat + Lapatinib + Trastuzumab |
Indication/Tumor Type | Her2-receptor positive breast cancer |
Response Type | sensitive |
Drug Indications | antineoplastic agent |
Drug Class | Small molecule |
FDA Approval | not approved |
CHEMBL27759 | ChEMBL Drug ID |
D0M8FD | TTD Drug ID |
ENTINOSTAT | Primary Drug Name |
ENTINOSTAT | Drug Generic Name |
MS-275 | Drug Synonym |